"Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study." . . "1" . "15110" . . . "PURPOSE: Bmi-1 is a Polycomb group member which participates in many physiological processes as well as in a wide spectrum of cancers. The aim of this study was to investigate Bmi-1 expression in non-small cell lung cancer (NSCLC) in respect to clinicopathological features and therapeutic outcomes. METHODS: Immunohistochemical staining for Bmi-1 was performed on tissue microarrays (TMAs) constructed from 179 formalin-fixed and paraffin-embedded NSCLC samples (106 squamous, 58 adeno-, and 15 large cell carcinomas). Data were subject to statistical analysis by SPSS. RESULTS: Overall evaluation of all tumor cases showed that 20 (11.43%) were negative, 37 (21.14%) showed weak, 65 (37.14%) moderate and 57 (32.57%) strong nuclear positivity for Bmi-1. Statistical analysis of our data revealed that the expression of Bmi-1 was significantly higher in stage III (P = 10(-6)) and stage IV (P = 10(-5)) tumors compared to stages I and II tumors. The administration of adjuvant chemotherapy significantly increased D"@en . . "Prognostick\u00E1 hodnota Bmi-1 onkoproteinov\u00E9 exprese u NSCLC pacient\u016F: a tissue microarray study."@cs . "Prognostick\u00E1 hodnota Bmi-1 onkoproteinov\u00E9 exprese u NSCLC pacient\u016F: a tissue microarray study."@cs . . "Prognostic value of Bmi-1 oncoprotein expression"@en . "Radov\u00E1, Lenka" . "RIV/61989592:15110/08:00006169" . "[3EF3BCA5A4A4]" . . . "Fridman, E." . "Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study." . . "P(NR8370), P(NR8425), S, Z(MSM6198959216)" . "Ehrmann, Ji\u0159\u00ED" . "0171-5216" . "Kol\u00E1\u0159, Zden\u011Bk" . "RIV/61989592:15110/08:00006169!RIV09-MZ0-15110___" . . "Klein, Ji\u0159\u00ED" . . . . . "Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study."@en . . "Murray, P. G." . . "1" . . "12"^^ . "390192" . "PURPOSE: Bmi-1 is a Polycomb group member which participates in many physiological processes as well as in a wide spectrum of cancers. The aim of this study was to investigate Bmi-1 expression in non-small cell lung cancer (NSCLC) in respect to clinicopathological features and therapeutic outcomes. METHODS: Immunohistochemical staining for Bmi-1 was performed on tissue microarrays (TMAs) constructed from 179 formalin-fixed and paraffin-embedded NSCLC samples (106 squamous, 58 adeno-, and 15 large cell carcinomas). Data were subject to statistical analysis by SPSS. RESULTS: Overall evaluation of all tumor cases showed that 20 (11.43%) were negative, 37 (21.14%) showed weak, 65 (37.14%) moderate and 57 (32.57%) strong nuclear positivity for Bmi-1. Statistical analysis of our data revealed that the expression of Bmi-1 was significantly higher in stage III (P = 10(-6)) and stage IV (P = 10(-5)) tumors compared to stages I and II tumors. The administration of adjuvant chemotherapy significantly increased D" . "9"^^ . "Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study."@en . . . "Kopolovic, J." . . . . "Kolek, Vit\u011Bzslav" . "Kn\u00ED\u017Eetov\u00E1, Petra" . "Journal of cancer research and clinical oncology" . "Vrzal\u00EDkov\u00E1, Kate\u0159ina" . "\u0160karda, Jozef" . . "DE - Spolkov\u00E1 republika N\u011Bmecko" . "15"^^ . "Hajd\u00FAch, Mari\u00E1n" . . "C\u00EDl: Bmi-1 je \u010Dlen polykomb. skupiny, ktr\u00E1 se \u00FA\u010Dastn\u00ED mnoha fyziologick\u00FDch proces\u016F, stejn\u011B jako v \u0161irok\u00E9m spektru druh\u016F rakoviny. C\u00EDlem t\u00E9to studie bylo prozkoumat Bmi-1 expresi u nemalobun\u011B\u010Dn\u00E9 rakoviny plic (NSCLC) s ohledme na klinickopatologick\u00E9 znaky a terapeutick\u00E9 z\u00E1v\u011Bry."@cs . . .